Search Results - immunotoxin

9 Results

Sort By:

Increased Therapeutic Effectiveness of PE-Based Immunotoxins

Abstract: Patients receiving immunotoxin cancer therapy are less likely to experience the deleterious side-effects associated with non-discriminate therapies such as chemotherapy or radiation therapy. Unfortunately, the continued administration of immunotoxins often leads to a reduced patient response due to the formation of neutralizing antibodies...

Published: 5/21/2024 | Inventor(s): Ira Pastan, Masanori Onda, Wenhai Liu

Keywords(s): B-CELL, CHEMOTHERAPY, Human B cell epitopes, Immunogenic epitopes, Immunotoxin, Pseudomonas exotoxin A, T-cell

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology

Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma

Abstract: Neuroblastoma is a rare pediatric cancer that affects one in every hundred thousand children under the age of fifteen in the United States. Current standards of care are chemotherapy and surgery, followed by stem-cell treatments, radiation and anti-ganglioside antibody therapy, which yield an average three-year survival rate of 10-45%. This...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Nan Li, Dimiter Dimitrov

Keywords(s): ADC, ANTIBODY, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, Glypican-2, GPC2, Immunotoxin, Neuroblastoma, Recombinant Immunotoxin, Rit

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology

High Affinity Monoclonal Antibodies Targeting Glypican-2 for Treating Childhood Cancers

Abstract: Neuroblastoma is a rare pediatric cancer with approximately 1,000 new cases arising annually. Current therapies have a less than forty-five percent (45%), three-year survival rate which demonstrate a need for a more effective treatment against this disease. Glypican-2 (GPC2) is a cell surface protein that is preferentially expressed in pediatric...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Nan Li, Bryan Fleming

Keywords(s): ADC, Antibody-drug Conjugate, CAR, chimeric antigen receptor, Glypican 2, GPC2, HO, Immunotoxin, Medulloblastoma, Neuroblastoma, Recombinant Immunotoxin, Retinoblastoma, Rit

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing

Improved PE-based Targeted Toxins: A Therapeutic with Increased Effectiveness

Abstract: Targeted toxins (e.g., immunotoxins) are therapeutics that have at least two important components: (1) a toxin domain that is capable of killing cells and (2) a targeting domain that is capable of selectively localizing the toxic domain to only those cells which should be killed. By selecting a targeting domain that binds only to certain diseased...

Published: 5/21/2024 | Inventor(s): Ira Pastan, Richard Beers, Masanori Onda

Keywords(s): Breast, HEAD, Hematological cancer, Immunotoxin, Ligand-targeted toxin, LUNG, NECK, OVARIAN, Toxin domain

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Cardiology

High Affinity Monoclonal Antibodies Targeting Glypican-1

Abstract: Pancreatic cancer is the fourth most common cause of death from cancer in the U.S. The overall 5-year survival rate for this disease is 8.5%. Glypican-1 (GPC1), a cell surface heparan sulfate proteoglycan protein that is overexpressed in pancreatic cancer. Due to this preferential expression, GPC1 represents a potential candidate for targeted...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Nan Li

Keywords(s): ADC, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, Glypican-1, GPC1, HO, Immunotoxin, NANOBODY, Pancreatic Cancer, Recombinant Immunotoxin, Rit, Single Domain Antibody

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics

A Fold-Back Diabody Format for Diphtheria Toxin-Based Immunotoxins That Can Increase Binding and Potency

NIH inventors, in collaboration with Scott and White Memorial Hospital inventors, have developed new immunotoxins comprising a mutant diphtheria toxin linked to an anti-prostate specific membrane antigen (PSMA) fold-back diabody. The fold-back diabody construct has a shortened linker region between the heavy and light chains of the antibody variable...

Published: 7/25/2024 | Inventor(s): David Neville

Keywords(s): A-dmDT390scfbDb591, Anti-prostratic, APPLICATION, Based, BINDING, CANCER, CB1AXX, CB1BXX, CB1CXX, CB1XXX, CBXXXX, CXXXXX, Diabody, DIPHTHERIA, Diptheria, Fold-back, FORMAT, Immunotoxin, IMMUNOTOXINS, INCREASE, particular, Potentcy, That, toxin

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics

Methods of Inducing Immune Tolerance Using Immunotoxins

The invention concerns immunotoxins and methods of using the immunotoxins for the treatment of rejection response in a patient, including graft-versus-host disease and transplantation of organs, tissues and cells into a host. In a specific embodiment of the invention, the transplant involves pancreatic islet cells. The immunotoxins are targeted via...

Published: 7/25/2024 | Inventor(s): David Neville

Keywords(s): Activity, Agents, CB1XXX, CBXXXX, Cell, COMBINED, CXXXXX, Dendritic, Graft versus host disease, IB3XXX, IBXXXX, IMMUNE, Immunotoxin, IMMUNOTOXINS, Induce, INDUCING, INHIBIT, IN-VIVO, ISLET, IXXXXX, Maturation, Methds, Method, Methods, Novel, Pancreatic, RELATED, SUPPRESSANT, T, That, TOLERANCE, TRANSPLANTATION

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics, TherapeuticArea > Oncology, Application > Therapeutics

Methods for Expression and Purification of Immunotoxins

The invention concerns immunotoxins and methods of making the immunotoxins. Targeting of the immunotoxins occurs via an antibody that is specific to T cells. This allows the specific ablation of malignant T cells and resting T cells. The transient ablation of resting T cells can "reset" the immune system by accentuating tolerizing responses. As...

Published: 7/25/2024 | Inventor(s): David Neville

Keywords(s): Aplastic anemia, Are, Bivalent, CB6XXX, CBXXXX, COMPLEX, CXXXXX, ESSENTIAL, Graft versus host disease, IB3XXX, IBXXXX, Immunotoxin, IXXXXX, LOW, lymphoma, Media, PASTORIS, PICHIA, production, temperature

Category(s): Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Immunology, Application > Diagnostics, Application > Therapeutics, TherapeuticArea > Oncology

Immunotoxin with in-vivo T cell Suppressant Activity

The invention concerns immunotoxins and methods of using the immunotoxins for the treatment of autoimmune diseases and T cell malignancies. The immunotoxins are targeted via an antibody that is specific to T cells. This allows the specific ablation of malignant T cells and resting T cells. The transient ablation of resting T cells can "reset" the...

Published: 7/25/2024 | Inventor(s): David Neville

Keywords(s): Activity, Aplastic anemia, CB1XXX, CBXXXX, Cell, CXXXXX, IB3XXX, IBXXXX, IMMUNE, Immunotoxin, IMMUNOTOXINS, INDUCING, IN-VIVO, IXXXXX, lymphoma, Methods, Novel, SUPPRESSANT, T, TOLERANCE, UAXXXX, Vivo

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, TherapeuticArea > Immunology, TherapeuticArea > Rare / Neglected Diseases, Application > Diagnostics, Application > Research Materials, Application > Therapeutics